BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Aventis  Pharma  Deutschland  GmbH  submitted  on  5  June  2003  an  application  for 
Marketing Authorisation to the European Medicines Agency (EMEA) for Apidra, in accordance with 
the centralised procedure falling within  the  scope of  Part A  of the  Annex to Council Regulation No 
(EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. Ian Hudson 
Co-Rapporteur:  Dr. Steffen Thirstrup 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 23 June 2003 
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CHMP  Members  on  
16  September  2003.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CHMP 
Members on 10 September 2003. 
During the meeting on 22 October 2003 the CHMP agreed on the consolidated list of questions 
to be sent to the company. The final consolidated list of questions was sent to the company on 
23 October 2003. 
The company submitted the responses to the consolidated list of questions on 22 January 2004. 
The  Rapporteurs  circulated the response assessment report  on the  company’s responses  to the 
list of questions to all CHMP Members on 25 February 2004. 
During the CHMP meeting on 24 March 2004, the CHMP agreed on a list of outstanding issues 
to be addressed in writing and/or oral explanation by the applicant. 
During the meeting on 01-03 June 2004, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Apidra on 3 June 2004. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 27 September 2004. 
1/1 
EMEA 2005 
 
 
